Abstract
Background Breakthrough cancer pain (BTcP) represents an important clinical challenge in the care of patients with cancer. Oral opioids have traditionally been the only available drugs for BTcP. However, the onset and duration of action of oral opioids may not be suitable for treating many episodes of BTcP in patients with bone metastases that are of short onset and duration. Aim of this study was to investigate the efficacy and long-term tolerability of intranasal fentanyl spray (INFS) 50 to 200 microg in the treatment of breakthrough pain in opioid-tolerant patients with lung cancer and bone metastases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
